4-(6-fluoro-5-methylpyridin-3-yl)-6,7-dimethoxycinnoline | 1119718-08-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(6-fluoro-5-methylpyridin-3-yl)-6,7-dimethoxycinnoline
• CAS: 1119718-08-9
• 化学式: C₁₆H₁₄FN₃O₂
• 分子量: 299.304
• InChiKey: GGRQWRSALXCWCF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  57.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(6-fluoro-5-methylpyridin-3-yl)-6,7-dimethoxycinnoline 在 sodium hydride 、 potassium carbonate 作用下， 以 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 48.17h， 生成 N-(2,2-difluoroethyl)-5-(6,7-dimethoxycinnolin-4-yl)-N-ethyl-3-methylpyridin-2-amine
  参考文献：
  名称：

  快速鉴定新型小分子磷酸二酯酶10A（PDE10A）示踪剂

  摘要：

  放射性标记的示踪剂，用于在大脑中成像治疗靶标，是在中枢神经系统药物发现中进行铅优化和在临床开发中选择剂量的重要工具。我们报告了使用LC-MS / MS技术对新型磷酸二酯酶10A（PDE10A）示踪剂候选物的快速鉴定。这种结构独特的PDE10A示踪剂AMG-7980（5）已显示在纹状体中具有良好的摄取（1.2％ID / g组织），高特异性（纹状体/丘脑比例为10）和体内可饱和结合。使用[ 3 H] 5确定PDE10A亲和力（K D）和PDE10A目标密度（B max）分别为0.94 nM和2.3 pmol / mg蛋白。对大鼠纹状体匀浆。大鼠脑切片的放射自显影表明示踪信号与已知的PDE10A表达模式一致。[ 3 H] 5与大鼠脑的特异性结合被另一种在结构上不同的已发表的PDE10A抑制剂MP-10阻断。最后，使用LC-MS / MS技术，我们的示踪剂用于测量大鼠中PDE10A抑制剂在体内的PDE10A靶标占有率。

  DOI：

  10.1021/jm3002372
• 作为产物：
  描述：

  2'-氨基-4',5'-二甲氧基苯乙酮 在 盐酸 、 四(三苯基膦)钯 、 caesium carbonate 、 sodium nitrite 、 三溴氧磷 作用下， 以 乙二醇二甲醚 、 水 、 乙腈 为溶剂， 生成 4-(6-fluoro-5-methylpyridin-3-yl)-6,7-dimethoxycinnoline
  参考文献：
  名称：

  发现有效，选择性和代谢稳定的4-（吡啶-3-基）肉桂醛作为新型磷酸二酯酶10A（PDE10A）抑制剂

  摘要：

  我们报告发现6,7-二甲氧基-4-（吡啶-3-基）cinnolines作为磷酸二酯酶10A（PDE10A）的新型抑制剂。对结构-活性关系的系统检查和分析导致抗PDE10A的位数为nM。X射线共晶体结构揭示了酶催化结构域中的结合模式以及对其他PDE的选择性来源。借助代谢物鉴定（ID）研究解决了大鼠体内高清除率的问题。这些发现共同产生了化合物39，它是一种有前途的有效PDE10A抑制剂，在大鼠中具有良好的体内代谢稳定性，并在啮齿动物行为模型中具有功效。

  DOI：

  10.1016/j.bmcl.2012.01.086

文献信息

• Discovery of potent, selective, and metabolically stable 4-(pyridin-3-yl)cinnolines as novel phosphodiesterase 10A (PDE10A) inhibitors
  作者：Essa Hu、Roxanne K. Kunz、Shannon Rumfelt、Ning Chen、Roland Bürli、Chun Li、Kristin L. Andrews、Jiandong Zhang、Samer Chmait、Jeffrey Kogan、Michelle Lindstrom、Stephen A. Hitchcock、James Treanor

  DOI：10.1016/j.bmcl.2012.01.086

  日期：2012.3

  We report the discovery of 6,7-dimethoxy-4-(pyridin-3-yl)cinnolines as novel inhibitors of phosphodiesterase 10A (PDE10A). Systematic examination and analyses of structure–activity-relationships resulted in single digit nM potency against PDE10A. X-ray co-crystal structure revealed the mode of binding in the enzyme’s catalytic domain and the source of selectivity against other PDEs. High in vivo clearance

  我们报告发现6,7-二甲氧基-4-（吡啶-3-基）cinnolines作为磷酸二酯酶10A（PDE10A）的新型抑制剂。对结构-活性关系的系统检查和分析导致抗PDE10A的位数为nM。X射线共晶体结构揭示了酶催化结构域中的结合模式以及对其他PDE的选择性来源。借助代谢物鉴定（ID）研究解决了大鼠体内高清除率的问题。这些发现共同产生了化合物39，它是一种有前途的有效PDE10A抑制剂，在大鼠中具有良好的体内代谢稳定性，并在啮齿动物行为模型中具有功效。
• PHOSPHODIESTERASE 10 INHIBITORS
  申请人：Hu Essa

  公开号：US20090062277A1

  公开（公告）日：2009-03-05

  The present invention is directed to certain compounds useful as phosphodiesterase 10 (PDE10) inhibitors that have the formula where R 1 , R 2 , R 3 , R 4 , X, Y and Z are as defined herein, pharmaceutical compositions containing such compounds and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  本发明涉及一些化合物，这些化合物可用作磷酸二酯酶10（PDE10）抑制剂，其具有以下结构式：其中R1、R2、R3、R4、X、Y和Z如本文所定义，包含这些化合物的药物组合物以及制备这些化合物的方法。该发明还涉及治疗由PDE10介导的疾病的方法，如肥胖、非胰岛素依赖性糖尿病、精神分裂症、躁郁症、强迫症等。
• Use of structure based design to increase selectivity of pyridyl-cinnoline phosphodiesterase 10A (PDE10A) inhibitors against phosphodiesterase 3 (PDE3)
  作者：Essa Hu、Roxanne K. Kunz、Shannon Rumfelt、Kristin L. Andrews、Chun Li、Stephen A. Hitchcock、Michelle Lindstrom、James Treanor

  DOI：10.1016/j.bmcl.2012.09.010

  日期：2012.11

  We report our successful effort to increase the PDE3 selectivity of PDE10A inhibitor pyridyl cinnoline 1 using a combination of computational modeling and structural-activity relationship investigations. An analysis of the PDE3 catalytic domain compared to the co-crystal structure of cinnoline analog 1 in PDE10A revealed two areas of structural differences in the active sites and suggested areas on the scaffold that could be modified to exploit those unique structural features. Once SAR established the cinnoline as the optimal scaffold, modifications on the methoxy groups of the cinnoline and the methyl group on the pyridine led to the discovery of compounds 33 and 36. Both compounds achieved significant improvement in selectivity against PDE3 while maintaining their PDE10A inhibitory activity and in vivo metabolic stability comparable to 1. (C) 2012 Elsevier Ltd. All rights reserved.
• [EN] PHOSPHODIESTERASE 10 INHIBITORS<br/>[FR] INHIBITEURS DE PHOSPHODIESTÉRASE 10
  申请人：AMGEN INC

  公开号：WO2009025839A2

  公开（公告）日：2009-02-26

  The present invention is directed to compounds, useful as PDElO inhibitors, having the formula (I) where R1, R2, R3, R4, X, Y and Z are as defined herein, pharmaceutical compositions containing such compounds and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDElO, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
• [EN] PHOSPHODIESTERASE 10 INHIBITORS<br/>[FR] INHIBITEURS DE LA PHOSPHODIESTÉRASE 10
  申请人：AMGEN INC

  公开号：WO2009025823A1

  公开（公告）日：2009-02-26

  The present invention is directed to certain compounds useful as phosphodiesterase 10 (PDE10) inhibitors that have the formula (I), where R1, R2, R3, R4, X, Y and Z are as defined herein, pharmaceutical compositions containing such compounds and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.